- Home
- IAF vs CNTB Comparison
IAF vs CNTB Comparison
Compare IAF & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAF | CNTB |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.3M | 140.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IAF | CNTB |
|---|---|---|
| Price | $12.68 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 19.6K | ★ 1.7M |
| Earning Date | 01-01-0001 | 08-13-2026 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.36 | $1.06 |
| 52 Week High | $14.54 | $3.82 |
Technical Indicators
Market Signals| Indicator | IAF | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 29.96 |
| Support Level | $12.66 | N/A |
| Resistance Level | $13.21 | $2.78 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 16.87 | 0.00 |
Price Performance
Historical ComparisonAbout IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.